
ADMA Biologics Inc (NASDAQ:ADMA) shares are trading higher Monday after the company announced it received U.S. Food and Drug Administration approval for its sixth plasma collection center.
The BioCenters plasma collection facility located in Myrtle Beach, South Carolina, commenced operations and initiated source plasma collection in the fourth quarter of 2021. Following Monday's approval, the facility is now able to collect human source plasma for further manufacturing in the U.S. and introduce the plasma into interstate commerce.